Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria
Top Cited Papers
- 3 October 2013
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (14), 1381-1382
- https://doi.org/10.1056/nejmc1301936
Abstract
Primaquine is the only medication approved by the Food and Drug Administration to eradicate the hypnozoites of Plasmodium vivax, but relapses of P. vivax malaria due to drug failure occur.1 Human cytochrome P-450 isoenzyme 2D6 (CYP2D6) may be a key enzyme involved in metabolizing primaquine into redox-active metabolites against hypnozoites in the liver.2,3This publication has 5 references indexed in Scilit:
- CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquineMalaria Journal, 2012
- How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological TreatmentsCurrent Drug Metabolism, 2010
- Primaquine revisited six decades after its discoveryEuropean Journal of Medicinal Chemistry, 2009
- The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of PhenotypeClinical Pharmacology & Therapeutics, 2007
- Primaquine Therapy for MalariaClinical Infectious Diseases, 2004